US Patent Issued to Alnylam Pharmaceuticals on March 25 for "Complement component C3 iRNA compositions and methods of use thereof" (Massachusetts Inventors)

ALEXANDRIA, Va., March 26 -- United States Patent no. 12,258,565, issued on March 25, was assigned to Alnylam Pharmaceuticals Inc. (Cambridge, Mass.).

"Complement component C3 iRNA compositions and methods of use thereof" was invented by Mark Keating (Weston, Mass.), James D. McIninch (Burlington, Mass.), Elane Fishilevich (Rochester, Mass.), Kristina Yucius (Burlington, Mass.), Sarah Solomon (Cambridge, Mass.), Mark K. Schlegel (Boston), Adam Castoreno (Framingham, Mass.) and Charalambos Kaittanis (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the complement component C3 gene (C3). The inventi...